Nanjing Xinbai Expects First-Half 2026 Net Profit to Drop Over 77% Year-on-Year

Earnings
โดย 中国证券报·Read original
Summary · why it matters

Nanjing Xinbai has disclosed its earnings forecast, expecting attributable net profit for the first half of 2026 to be between 35.12 million yuan and 38.05 million yuan, a year-on-year decline of 77.15% to 78.9%. Deducted non-recurring net profit is expected to be between 6.62 million yuan and 9.55 million yuan, a year-on-year drop of 92.94% to 95.1%. The company stated that the decline in performance is mainly due to lower sales of the product PROVENGE by Dendreon Pharmaceuticals LLC, which is controlled by its wholly-owned subsidiary Shiding Biotechnology Hong Kong Company Limited, reducing Shiding Hong Kong's net profit by approximately 142 million yuan.

Impact on stocks 1

Others▼ · 1 stocks

Off-coverage companies 2

Dendreon Pharmaceuticals LLCPrivate▼ Negative
Demandrelevance

Dendreon's lower PROVENGE sales are the direct cause of the profit decline for its parent.

世鼎生物技术（香港）有限公司Private▼ Negative
Demandrelevance

Shiding Hong Kong's net profit reduced by ~142 million yuan due to lower PROVENGE sales.

© 2026 MarketDXNews